'低後悔'的說法被揭露為有缺陷—真正的去過渡率仍然未知

去過渡率未知

Authors
J. Cohn
Journal
Archives of Sexual Behavior
Year
2023

Summary

Low regret figures such as 0.3–0.6% are often quoted to show that detransition is rare. In this opinion piece, J. Cohn argues that the true rates are unknown. He sets four conditions for a sound study: long enough follow-up (published times to regret range from about 3 to over 10 years), few people lost along the way, clear definitions and suitable measures, and patients like today's, who are mostly teenage girls. None of the studies in a 2021 review of surgery regret followed at least 85% of people for 8 or more years. Studies reporting higher rates fail the same tests. It is a useful checklist for reading regret studies, but it offers argument, not new data. Some of its cut-offs are judgement calls, and the author works with SEGM (the Society for Evidence-Based Gender Medicine), which urges caution in youth gender medicine.

Key findings

  • Cohn 主張,性別相關醫療處置後停止、去過渡和後悔的比率目前並不清楚。他並沒有宣稱真實比率是高還是低。
  • 常被引用的 0.3–0.6% 後悔率主要來自在較舊、較嚴格規定下接受治療的成人,而不是現今的患者;現今的患者多半在青少年時期才首次出現性別困擾,而且以女性居多。
  • 已發表的後悔或去過渡所需時間很長:從去過渡者調查中的約 3 年,到荷蘭資料中切除睪丸或卵巢後平均將近 11 年,瑞典資料中的典型時間約為 7.5 至 8 年。
  • 以嚴格的至少 8 年為標準,2021 年一篇手術後悔回顧(Bustos 等人)中的研究,沒有一項追蹤到至少 85% 的患者,並且對所有人都追蹤 8 年以上。
  • 只計算仍在性別門診就診的人,或只調查仍自認為跨性別的人,會漏掉整群後悔或去過渡的人。在一項調查中,只有約四分之一的去過渡者告訴過他們的臨床人員。
  • 報告較高比率的研究,例如美國軍方資料中四年內近 30% 停用荷爾蒙,也達不到同樣的標準。
  • Cohn 的結論是,考慮醫療過渡的人應被告知後悔或去過渡的機率是未知的,並作為同意治療的一部分。

Conclusion

The detransition rate is unknown. Existing studies claiming low regret or detransition rates (0.3-0.6%) are unreliable due to methodological flaws including: insufficient follow-up time (often shorter than observed median times to regret of 7.5-8 years), high loss to follow-up, inappropriate measurement instruments, and non-representative samples that differ from current patient populations. The frequently quoted extremely low rates are based on studies with adults who underwent extensive screening under older protocols, not the current adolescent-onset cohort with different characteristics. Until properly designed long-term studies are conducted with adequate follow-up duration, small loss to follow-up, appropriate definitions and measurement tools, and relevant samples, the true rates of discontinuation, detransition, and regret cannot be determined. This uncertainty should be communicated to patients and families as part of informed consent for gender-affirming medical interventions.